What's in Tarsa Therapeutics, Inc.'s pipeline?

Tarsa Therapeutics, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Tarsa Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Eli Lilly and Company, University of Missouri-Columbia, Université de Montréal.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tarsa-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Tarsa Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Tarsa Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Oral Calcitonin Tablets	Oral Calcitonin Tablets	phase 3	Calcitonin receptor agonist	Calcitonin receptor	Bone metabolism / Osteoporosis

Therapeutic area mix

Bone metabolism / Osteoporosis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eli Lilly and Company · 1 shared drug class
University of Missouri-Columbia · 1 shared drug class
Université de Montréal · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tarsa Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Tarsa Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tarsa-therapeutics-inc. Accessed 2026-05-16.